Form 4: Hookipa Pharma Inc. Executive Klaus Orlinger Reports Stock Option Grant

Chief Scientific Officer Klaus Orlinger reports the acquisition of stock options in Hookipa Pharma Inc.

Summary

• Klaus Orlinger, Chief Scientific Officer of Hookipa Pharma Inc., filed a Form 4 with the SEC.
• The filing reports the grant of stock options to Orlinger on April 15, 2024.
• Orlinger acquired options to purchase 367,300 shares of Hookipa Pharma Inc. common stock at an exercise price of $0.76 per share.
• The options vest 25% on April 15, 2025, and the remainder vests in 12 equal quarterly installments thereafter.
• Following the transaction, Orlinger directly owns options for 367,300 shares.

Sentiment

Score: 6

Explanation: The document is a routine filing related to executive compensation. It's neutral in tone and doesn't provide any information that would significantly impact investor sentiment positively or negatively.

Positives

• The grant of stock options to a key executive like the Chief Scientific Officer can align their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock option grants are a common practice in the pharmaceutical industry to incentivize key executives and align their interests with the long-term success of the company. This is a standard method of executive compensation.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotechnology and pharmaceutical industries.
• Companies like Moderna, BioNTech, and Gilead Sciences also utilize stock options to incentivize their executives.
• The vesting schedule and exercise price are generally determined based on industry benchmarks and the executive's role and performance.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised in the future.
• The grant incentivizes the Chief Scientific Officer to contribute to the company's success, which could benefit all stakeholders.

Key Dates